Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years-Reference-Cited by-同舟云学术

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years

Published:2014-04-29 Issue:7 Volume:10 Page:1795-1806
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Zhu Fengcai¹,Li Juan²,Hu Yuemei¹,Zhang Xiang³,Yang Xiaoping⁴,Zhao Hui²,Wang Junzhi²,Yang Jianguo³,Xia Guodong⁴,Dai Qinyong⁵,Tang Haiwen⁶,V Suryakiran Pemmaraju⁷,Datta Sanjoy K⁸,Descamps Dominique⁸,Bi Dan⁸,Struyf Frank⁸

Affiliation:

1. Center for Disease Prevention and Control; Nanjing City, Jiangsu Province, PR China

2. National Institute for Food and Drug Control; Beijing, PR China

3. Center for Disease Prevention and Control; Taizhou City, Jiangsu Province, PR China

4. Center for Disease Control and Prevention; Jintan City, Jiangsu Province, PR China

5. Roche Hong Kong Ltd; Hong Kong, PR China

6. GlaxoSmithKline Vaccines; Shanghai, PR China

7. GlaxoSmithKline Vaccines; Bangalore, India

8. GlaxoSmithKline Vaccines; Wavre, Belgium

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.4161/hv.28702

Reference45 articles.

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed on 17 December 2013.

2. The burden of cervical cancer in China: Synthesis of the evidence

3. Human papillomaviruses in the pathogenesis of anogenital cancer

4. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

5. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Non-inferiority of Human Papillomavirus Vaccine Immunogenicity Among Women Over 26 Years: A Systematic Review;Cureus;2024-07-22

2. Different dose series of human papillomavirus vaccine in young females: a pair-wise meta-analysis and network meta-analysis from randomized controlled trials;Frontiers in Public Health;2023-09-21

3. A feasibility assessment of real‐world data capabilities for monitoring vaccine safety and effectiveness in China: Human papillomavirus vaccination in the Yinzhou district as a use case;Pharmacoepidemiology and Drug Safety;2023-06-15

4. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9–45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial;Vaccine;2023-05

5. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China;Frontiers in Immunology;2023-03-13